303 related articles for article (PubMed ID: 25590271)
21. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
[TBL] [Abstract][Full Text] [Related]
22. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
[TBL] [Abstract][Full Text] [Related]
23. Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Prasitsuebsai W; Teeraananchai S; Singtoroj T; Truong KH; Ananworanich J; Do VC; Nguyen LV; Kosalaraksa P; Kurniati N; Sudjaritruk T; Chokephaibulkit K; Kerr SJ; Sohn AH
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):380-6. PubMed ID: 27355415
[TBL] [Abstract][Full Text] [Related]
24. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Gilks CF; Walker AS; Dunn DT; Gibb DM; Kikaire B; Reid A; Musana H; Mambule I; Kasirye R; Robertson V; Ssali F; Spyer M; Pillay D; Yirrell D; Kaleebu P;
Antivir Ther; 2012; 17(7):1363-73. PubMed ID: 22814125
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
26. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Meyers TM; Yotebieng M; Kuhn L; Moultrie H
Pediatr Infect Dis J; 2011 Nov; 30(11):974-9. PubMed ID: 21734620
[TBL] [Abstract][Full Text] [Related]
28. Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Gumede SB; Fischer A; Venter WDF; Lalla-Edward ST
S Afr Med J; 2019 Nov; 109(12):919-926. PubMed ID: 31865953
[TBL] [Abstract][Full Text] [Related]
29. Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia.
Teeraananchai S; Law M; Boettiger D; Mata N; Gupte N; Chan YL; Pham TN; Chaiwarith R; Ly PS; Chan YJ; Kiertiburanakul S; Khusuwan S; Zhang F; Yunihastuti E; Kumarasamy N; Pujari S; Azwa I; Somia IKA; Tanuma J; Ditangco R; Choi JY; Ng OT; Do CD; Gani Y; Ross J; Jiamsakul A;
J Int AIDS Soc; 2022 Aug; 25(8):e25989. PubMed ID: 36028921
[TBL] [Abstract][Full Text] [Related]
30. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Hosseinipour MC; Kumwenda JJ; Weigel R; Brown LB; Mzinganjira D; Mhango B; Eron JJ; Phiri S; van Oosterhout JJ
HIV Med; 2010 Sep; 11(8):510-8. PubMed ID: 20345885
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
32. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Parienti JJ; Barrail-Tran A; Duval X; Nembot G; Descamps D; Vigan M; Vrijens B; Panhard X; Taburet AM; Mentré F; Goujard C
Antimicrob Agents Chemother; 2013 May; 57(5):2265-71. PubMed ID: 23459496
[TBL] [Abstract][Full Text] [Related]
33. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
34. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
36. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
Haas DW; Zala C; Schrader S; Piliero P; Jaeger H; Nunes D; Thiry A; Schnittman S; Sension M;
AIDS; 2003 Jun; 17(9):1339-49. PubMed ID: 12799555
[TBL] [Abstract][Full Text] [Related]
37. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.
Nsanzimana S; Semakula M; Ndahindwa V; Remera E; Sebuhoro D; Uwizihiwe JP; Ford N; Tanner M; Kanters S; Mills EJ; Bucher HC
BMC Infect Dis; 2019 Apr; 19(1):312. PubMed ID: 30953449
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
39. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
[TBL] [Abstract][Full Text] [Related]
40. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
